Our
News
Check back on a regualr basis
for futher updates.
UK MHRA Scientific Advice on Pivotal Trial of NG13-2, a Novel Product for the Prevention of Chemotherapy-Induced Alopecia
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that the company has received the notification of the Date for Scientific Advisory meeting from the MHRA on the NG13-2 programme for the prevention of chemotherapy-induced alopecia.
UK MHRA Scientific Advice on Pivotal Trial of NG11-2, a Novel Product for the Prevention of Oral Mucositis
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that the company has received supportive feedback from the MHRA on the approach to a pivotal Phase 2b/3 trial and market approval for NG11-2, a novel product for the prevention of severe oral mucositis induced by radiotherapy.
VasoDynamics receives PING Innovation Award 2025
VasoDynamics awarded the Innovation of the Year 2025 by the Pharmaceutical Industry Network Group (PING) after its successful clinical trial showing prevention of severe oral mucositis induced by radiotherapy in patients with head and neck cancers.
NG11-2 Phase Ib clinical study in oral mucositis: UK MHRA confirms Scientific Advisory review meeting for June with feedback in late July 2025
NG11-2 Phase Ib clinical study in oral mucositis: UK MHRA confirms Scientific Advisory review meeting for June with feedback in late July 2025
NG11-2 Phase-Ib Clinical Study Results Summary Available
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
NG11-2 Phase-Ib Clinical Study Report Complete
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer